Loading…
CORONA Remedies (CORONA)₹2,539+0.21%Pharmaceuticals
In the Sep 2026 quarter (consolidated), CORONA Remedies reported sales of ₹441 Cr, up 22.3% from Sep 2025, and net profit of ₹59.89 Cr, up 15.3% year on year. For the year to Mar 2026, sales were ₹1,403 Cr and net profit ₹185 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 314 | 298 | 294 | 347 | 361 | 342 | 353 | 422 | 441 |
| Expenses | 247 | 228 | 239 | 277 | 283 | 259 | 292 | 330 | 346 |
| Operating Profit | 67.07 | 69.08 | 54.03 | 70.01 | 78.01 | 83.04 | 61.99 | 93.01 | 96.11 |
| OPM % | 21.0% | 22.9% | 18.0% | 20.0% | 22.0% | 24.0% | 18.0% | 22.0% | 21.9% |
| Other Income | 2.01 | 1.01 | 2.01 | 2.01 | 2.01 | −17.04 | 4.01 | 3.01 | 3.01 |
| Interest | 3.01 | 2.01 | 2.01 | 2.01 | 2.01 | 2.01 | 1.01 | 3.01 | 3.01 |
| Depreciation | 8.99 | 9.99 | 9.98 | 8.98 | 8.98 | 8.99 | 9.99 | 12.98 | 14.97 |
| Profit before tax | 57.14 | 58.15 | 44.15 | 61.18 | 70.23 | 55.19 | 55.16 | 80.23 | 81.28 |
| Tax % | 25.0% | 23.0% | 28.0% | 24.0% | 25.0% | 25.0% | 17.0% | 25.0% | 25.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −12.98 | 0.00 | 0.00 | 0.00 |
| Net Profit | 42.93 | 44.96 | 31.96 | 45.95 | 51.96 | 40.95 | 44.92 | 59.88 | 59.89 |
| EPS (Rs) | 7.04 | 7.36 | 5.17 | 7.56 | 8.56 | 6.76 | 7.42 | 9.84 | 9.87 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|
| Sales | 884 | 1,013 | 1,195 | 1,403 | 1,559 |
| Expenses | 757 | 860 | 957 | 1,111 | 1,226 |
| Operating Profit | 128 | 156 | 241 | 294 | 334 |
| OPM % | 14.0% | 14.9% | 20.0% | 21.0% | 21.4% |
| Other Income | 7.02 | 5.01 | 6.02 | −9.03 | −7.01 |
| Interest | 4.01 | 14.01 | 11.01 | 7.01 | 9.04 |
| Depreciation | 19.96 | 27.98 | 36.93 | 37.95 | 46.93 |
| Profit before tax | 111 | 118 | 200 | 241 | 272 |
| Tax % | 23.0% | 24.0% | 25.0% | 23.0% | — |
| Exceptional items | 0.00 | −0.99 | −0.99 | −14.99 | −12.98 |
| Net Profit | 84.83 | 89.92 | 149 | 185 | 206 |
| EPS (Rs) | 13.90 | 14.82 | 24.45 | 30.28 | 33.89 |
| Dividend payout % | 20.0% | 25.0% | 30.0% | 33.0% | — |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 60.76 | 60.77 | 60.77 | 60.77 |
| Reserves | 347 | 419 | 545 | 684 |
| Borrowings | 27.87 | 158 | 85.65 | 164 |
| Other Liabilities | 158 | 190 | 236 | 292 |
| Total Liabilities | 594 | 829 | 928 | 1,201 |
| Fixed Assets | 184 | 383 | 369 | 551 |
| CWIP | 65.27 | 121 | 187 | 143 |
| Investments | 31.89 | 25.94 | 25.91 | 25.92 |
| Other Assets | 313 | 300 | 347 | 480 |
| Inventories | 105 | 97.67 | 129 | 124 |
| Trade receivables | 87.31 | 100 | 119 | 147 |
| Cash & equivalents | 77.05 | 70.01 | 69.01 | 43.98 |
| Total Assets | 594 | 829 | 928 | 1,201 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from operating activity | 103 | 156 | 189 | 228 |
| Cash from investing activity | −49.86 | −266 | −83.84 | −256 |
| Cash from financing activity | −45.16 | 99.40 | −107 | 25.11 |
| Net cash flow | 8.01 | −11.01 | 0.00 | −1.01 |
| Capex | 94.68 | 285 | 91.64 | 173 |
| Free cash flow | 9.03 | −129 | 99.31 | 56.23 |
| CFO / OP % | 100.0% | 111.9% | 96.9% | 94.9% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor days | 36 | 36 | 36 | 38 |
| Inventory days | 181 | 157 | 199 | 174 |
| Days payable | 163 | 184 | 221 | 206 |
| Cash conversion cycle | 54 | 9 | 13 | 6 |
| Working capital days | 30 | −2 | 9 | −15 |
| ROCE % | — | 25.0% | 32.0% | 33.0% |
For the Sep 2026 quarter, CORONA Remedies reported sales of ₹441 Cr, up 22.3% year on year and net profit of ₹59.89 Cr, up 15.3% year on year. The operating margin was 21.9%.
CORONA Remedies' sales for the year to Mar 2026 were ₹1,403 Cr; over the last twelve months they were ₹1,559 Cr.
Net profit for the year to Mar 2026 was ₹185 Cr, and ₹206 Cr over the last twelve months. Earnings per share over the same trailing period were ₹33.89.
CORONA Remedies reported borrowings of ₹164 Cr at Mar 2026, against cash and equivalents of ₹43.98 Cr.
Cash from operations was ₹228 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹56.23 Cr.